摘要
目的 系统评价含哌拉西林制剂引起的不良反应(ADRs)情况。方法 计算机检索PubMed、EMbase、Web of Science、CNKI、WanFang Data和VIP数据库,搜集含哌拉西林制剂引起ADRs的案例报告,检索时限均为建库至2021年12月31日。由2名研究者独立筛选文献、提取资料后,进行定性系统评价。结果 共纳入168个案例报告,包括170例患者,男女比为1.06∶1,中位年龄54岁。定性系统评价结果显示,哌拉西林ADRs多累及全身(n=55),其次是血液系统(n=48)、皮肤及软组织系统(n=39)和神经系统(n=18)。ADRs报道最多的是过敏性休克(n=29),其次为药物热(n=19)、皮疹(n=17)和血小板减少(n=15)。最严重的ADRs是过敏性休克(n=29)和大疱表皮坏死性松解症(n=6)。结论 当前有限证据显示,含哌拉西林制剂ADRs多累及全身,最严重的ADRs包括表皮坏死性松解症和过敏性休克。
Objective To systematically review the adverse drug reactions(ADRs) caused by piperacillin.Methods PubMed, EMbase, Web of Science, CNKI, WanFang Data and VIP databases were electronically searched to collect case reports on ADRs caused by piperacillin from inception to December 31, 2021. Two reviewers independently screened literature, extracted data and then a qualitative systematic review was performed. Results A total of 168 case reports involving 170 patients were included. The male to female ratio was 1.06∶1, and the median age was 54 year old.The statistical results showed that ADRs caused by piperacillin mostly involved the whole body(n=55), followed by the blood system(n=48), skin and soft tissue system(n=39) and nervous system(n=18). The most frequently reported cases were anaphylactic shock(n=29), followed by drug fever(n=19), rash(n=17) and thrombocytopenia(n=15). The most serious ADRs were anaphylactic shock(n=29) and bullous epidermal necrolysis(n=6). Conclusion Current evidence shows that ADRs caused by piperacillin mostly involved the whole body and the most serious ADRs are toxic epidermal necrolysis and anaphylactic shock.
作者
张鸿儒
杨莉萍
ZHANG Hongru;YANG Liping(Department of Pharmacy,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application(Beijing Hospital),Beijing 100730,P.R.China;Department of Pharmacy,The First Hospital of Zhangjiakou,Zhangjiakou 075000,P.R.China)
出处
《中国循证医学杂志》
CSCD
北大核心
2023年第2期191-196,共6页
Chinese Journal of Evidence-based Medicine
基金
国家重点研发计划资助(编号:2020YFC2008306)。
关键词
哌拉西林
不良反应
个案报道
系统评价
Piperacillin
Adverse drug reactions
Case reports
Systematic review
